Early cancer drug trial halted after testing on 26 patients
NCT ID NCT06560632
Summary
This early-stage trial tested the safety of an experimental drug called RP-3467, both alone and combined with an existing cancer drug (olaparib), in adults with advanced solid tumors. The study aimed to find the highest safe dose and understand how the body processes the drug. It was terminated after enrolling 26 participants with specific types of advanced cancer that had stopped responding to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
# 1001, The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
# 1004, Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
# 1008, Columbia University
New York, New York, 10032, United States
-
# 1011, The Washington University
St Louis, Missouri, 63130, United States
-
# 1025, The University of California
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.